A team of researchers suggests that one dose of the Pfizer-BioNTech vaccine could be sufficient in providing a robust immune response 11 days after inoculation against severe acute respiratory syndrome (SARS-CoV-2).
According to the researchers, including Heidi E. Drummer from Monash University in Australia, the second ‘booster’ dose of the vaccine may not increase vaccine efficacy against SARS-CoV-2.
The findings, published as a preprint on the medRxiv* server, could help shape policy as vaccine rollout has been slow in countries such as the US and Canada. This could also increase with vaccine distribution efforts in developing countries where supplies have been scarce.
For the study, the team re-examined Pfizer-BioNTech phase III trial data from day 1 to 111 in the placebo and experimental groups.
They also looked at data from Moderna's vaccine trial. However, since the number of Covid-19 cases in the Moderna trial was low in the first few weeks, they did not have sufficient data to assess it.
Instead, Moderna's trial data was used for comparison purposes with Pfizer's trial data.
They studied the efficacy of vaccination from day 11 to day 28 and compared the efficacy of the second vaccine dose delivered on day 28 up to day 111.
The findings indicated that the first vaccine dose helped develop detectable neutralizing antibodies before the second dose, according to news-medical.net.
While Moderna's sample size was limited, compared with the Pfizer-BioNTech's mRNA vaccine, there continued to be no significant difference in vaccine efficacy between days 11 to 35 and 7 days after the second vaccine was administered, the study indicated.
(This story was published from a syndicated feed. Only the headline and picture has been edited by FIT).
(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)